ERRATUM
Erratum of Guidelines for the drug treatment of rheumatoid arthritis
Licia Maria Henrique da MotaI,* * Corresponding author. E-mail: liciamhmota@gmail.com (L.M.H Mota). ; Bóris Afonso CruzI; Claiton Viegas BrenolI; Ivânio Alves PereiraI; Lucila Stange Rezende-FronzaI; Manoel Barros BertoloI; Max Vitor Carioca FreitasI; Nilzio Antônio da SilvaI; Paulo Louzada-JuniorI; Rina Dalva Neubarth GiorgiI; Rodrigo Aires Corrêa LimaI; Wanderley Marques BernardoII; Geraldo da Rocha Castelar PinheiroI
ISociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil
IIAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil
In the original article, "Guidelines for the drug treatment of rheumatoid arthritis" (Rev Bras Reumatol 2013;53(2):158-183), where it reads:
Guidelines for the drug treatment of rheumatoid arthritis
Sociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology)
Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brazil
Participants
Licia Maria Henrique da Mota*, Bóris Afonso Cruz, Claiton Viegas Brenol, Ivânio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Vitor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgio, Rodrigo Aires Corrêa Lima, Wanderley Marques Bernardo, Geraldo da Rocha Castelar Pinheiro
It should read:
Guidelines for the drug treatment of rheumatoid arthritis
Licia Maria Henrique da Motaa,*, Bóris Afonso Cruza, Claiton Viegas Brenola, Ivânio Alves Pereiraa, Lucila Stange Rezende-Fronzaa, Manoel Barros Bertoloa, Max Vitor Carioca Freitasa, Nilzio Antônio da Silvaa, Paulo Louzada-Juniora, Rina Dalva Neubarth Giorgia, Rodrigo Aires Corrêa Limaa, Wanderley Marques Bernardob, Geraldo da Rocha Castelar Pinheiroa
aSociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil bAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil
At page 169, where it reads:
RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etarnecept (50 mg SC every two weeks), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).
it should reald:
RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etarnecept (50 mg SC weekly), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).
At page 172, table 5 [Portuguese edition only], where it reads:
It should read:
Publication Dates
-
Publication in this collection
16 Sept 2013 -
Date of issue
June 2013